FR3044017B1 - Procede de transfection transitoire pour la production retrovirale - Google Patents

Procede de transfection transitoire pour la production retrovirale Download PDF

Info

Publication number
FR3044017B1
FR3044017B1 FR1661254A FR1661254A FR3044017B1 FR 3044017 B1 FR3044017 B1 FR 3044017B1 FR 1661254 A FR1661254 A FR 1661254A FR 1661254 A FR1661254 A FR 1661254A FR 3044017 B1 FR3044017 B1 FR 3044017B1
Authority
FR
France
Prior art keywords
transient transfection
transfection method
bacs
retroviral production
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1661254A
Other languages
English (en)
French (fr)
Other versions
FR3044017A1 (fr
Inventor
Sabine Johnson
Celeste PALLANT
Eirini Vamva
Conrad Vink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1520764.0A external-priority patent/GB201520764D0/en
Priority claimed from GBGB1609354.4A external-priority patent/GB201609354D0/en
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of FR3044017A1 publication Critical patent/FR3044017A1/fr
Application granted granted Critical
Publication of FR3044017B1 publication Critical patent/FR3044017B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FR1661254A 2015-11-24 2016-11-21 Procede de transfection transitoire pour la production retrovirale Expired - Fee Related FR3044017B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1520764.0A GB201520764D0 (en) 2015-11-24 2015-11-24 Transient transfection method for retroviral production
GB15207640 2015-11-24
GB16093544 2016-05-26
GBGB1609354.4A GB201609354D0 (en) 2016-05-26 2016-05-26 Transient transfection method for retroviral production

Publications (2)

Publication Number Publication Date
FR3044017A1 FR3044017A1 (fr) 2017-05-26
FR3044017B1 true FR3044017B1 (fr) 2019-05-03

Family

ID=57348703

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1661254A Expired - Fee Related FR3044017B1 (fr) 2015-11-24 2016-11-21 Procede de transfection transitoire pour la production retrovirale

Country Status (15)

Country Link
US (2) US10450574B2 (enExample)
EP (1) EP3380605A1 (enExample)
JP (1) JP7110096B2 (enExample)
KR (1) KR102067352B1 (enExample)
CN (1) CN108291211A (enExample)
AU (1) AU2016359838B2 (enExample)
BR (1) BR112018010639A2 (enExample)
CA (1) CA3006285A1 (enExample)
DE (1) DE102016122317A1 (enExample)
FR (1) FR3044017B1 (enExample)
IL (1) IL259223B (enExample)
IT (1) IT201600117287A1 (enExample)
RU (1) RU2749717C2 (enExample)
SA (1) SA518391585B1 (enExample)
WO (1) WO2017089307A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986051C (fr) * 2015-05-15 2023-09-26 Vectalys Particule retrovirale comportant au moins deux arn non viraux encapsides
ES2939617T3 (es) * 2015-11-24 2023-04-25 Glaxosmithkline Ip Dev Ltd Líneas celulares estables para producción retroviral
GB201706121D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
GB201715052D0 (en) 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
ES2951857T3 (es) 2017-12-22 2023-10-25 Oxford Biomedica Ltd Vector retroviral
GB201816919D0 (en) * 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines
CN110684804B (zh) * 2019-10-15 2023-04-18 上海本导基因技术有限公司 递送外源rnp的慢病毒载体及其制备方法
GB202004371D0 (en) 2020-03-26 2020-05-13 Glaxosmithkline Ip Dev Ltd CAR constructs
GB202005096D0 (en) 2020-04-07 2020-05-20 Glaxosmithkline Modified vectors for production of retrovirus
AU2021253701B2 (en) * 2020-04-10 2024-05-02 Southwest Research Institute Three-dimensional bioreactor for viral vector production
CN117377691A (zh) 2021-03-19 2024-01-09 葛兰素史密斯克莱知识产权发展有限公司 靶向密蛋白3的嵌合抗原受体和治疗癌症的方法
CN113373266B (zh) * 2021-06-22 2022-07-01 内蒙古农业大学 一种用于检测绵羊肺腺瘤病毒的荧光rpa引物、试剂盒和检测方法
WO2024218341A1 (en) 2023-04-19 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for car-t and car-nk cells
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1995003400A1 (en) 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
ATE309000T1 (de) * 1995-06-27 2005-11-15 Bavarian Nordic As Verkapselte zellen die virenpartikeln produzieren
AU721326B2 (en) 1996-02-13 2000-06-29 Fred Hutchinson Cancer Research Center 10A1 retroviral packaging cells and uses thereof
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
US6277621B1 (en) 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences
PT1141315E (pt) 1998-12-31 2008-05-05 Novartis Vaccines & Diagnostic Polipéptidos do envelope (env) de hiv modificados
EP1179083A4 (en) 1999-04-22 2003-04-23 Gen Hospital Corp TRIPLE HYBRID AMPLICON VECTOR SYSTEMS FOR THE PRODUCTION OF RETROVIRUS PACKING CELL LINES
US6677155B1 (en) 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
CA2371946A1 (en) 1999-04-29 2000-11-09 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
CA2336590A1 (en) 1999-06-07 2000-12-14 Cell Genesys, Inc. Hybrid yeast-bacteria cloning system and uses thereof
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
WO2001091802A1 (en) 2000-05-30 2001-12-06 Baylor College Of Medicine Chimeric viral vectors for gene therapy
AU2001292711A1 (en) 2000-09-18 2002-03-26 Genetic Therapy, Inc. Stress resistant retroviruses
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002053576A1 (en) 2001-01-05 2002-07-11 The General Hospital Corporation Viral delivery system for infectious transfer of large genomic dna inserts
DE10111433A1 (de) 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
IL157746A0 (en) 2001-05-30 2004-03-28 Chromos Molecular Systems Inc Chromosome-based platforms
US6835568B2 (en) 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
JP4598398B2 (ja) 2002-02-01 2010-12-15 オックスフォード バイオメディカ （ユーケー） リミテッド ウイルスベクター
ATE471382T1 (de) 2002-04-10 2010-07-15 Us Gov Health & Human Serv Vac-bac-shuttlevektor-system
DE60314541T2 (de) * 2002-11-25 2008-02-28 Bavarian Nordic A/S Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
EP1743028A2 (en) * 2004-04-28 2007-01-17 The Trustees Of The University Of Pennsylvania Polyvalent viral vectors and a system for production thereof
US20080226677A1 (en) 2004-05-06 2008-09-18 Yasuko Mori Recombinant virus vector for gene transfer into lymphoid cells
EP1652932A1 (en) 2004-11-02 2006-05-03 GBF Gesellschaft für Biotechnologische Forschung mbH Method for the generation of virus producing cell lines and cell lines
AU2005309485A1 (en) 2004-11-24 2006-06-01 Nanovector Limited Viral vectors
PT2088193E (pt) * 2004-11-24 2011-02-24 Anaeropharma Science Inc Novo vector vaivém
EP2062246A4 (en) 2006-08-18 2010-09-29 Univ North Carolina VACCINES AGAINST CHIMARICAL VIRUSES
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
EP2137296A2 (en) 2007-03-23 2009-12-30 Wisconsin Alumni Research Foundation Somatic cell reprogramming
US20110027313A1 (en) 2008-04-04 2011-02-03 University Of Miami Viral recombineering and uses thereof
SI2480678T1 (sl) * 2010-09-02 2014-06-30 Molmed Spa Stabilno proizvajanje lentivirusnih vektorjev
US9273324B2 (en) 2010-12-05 2016-03-01 Andrew S. Belmont Recombinant gene expression
WO2012170431A2 (en) 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
JP2015529466A (ja) 2012-09-14 2015-10-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター
US10590433B2 (en) * 2014-03-14 2020-03-17 University Of Washington Genomic insulator elements and uses thereof
GB2538324A (en) 2015-05-15 2016-11-16 Glaxosmithkline Ip Dev Ltd Packaging cell line for retroviral production
GB2538321A (en) 2015-05-15 2016-11-16 Glaxosmithkline Ip Dev Ltd Artificial chromosome for retroviral production
KR102058113B1 (ko) * 2015-11-23 2019-12-23 주식회사 엘지화학 접착력이 개선된 리튬 이차전지용 전극 및 이의 제조방법
ES2939617T3 (es) 2015-11-24 2023-04-25 Glaxosmithkline Ip Dev Ltd Líneas celulares estables para producción retroviral

Also Published As

Publication number Publication date
BR112018010639A2 (pt) 2019-01-22
RU2749717C2 (ru) 2021-06-16
CA3006285A1 (en) 2017-06-01
CN108291211A (zh) 2018-07-17
AU2016359838B2 (en) 2020-08-06
IL259223A (en) 2018-07-31
RU2018118964A3 (enExample) 2020-04-02
FR3044017A1 (fr) 2017-05-26
US20200063144A1 (en) 2020-02-27
DE102016122317A1 (de) 2017-05-24
US20170145427A1 (en) 2017-05-25
KR20180073624A (ko) 2018-07-02
US10450574B2 (en) 2019-10-22
WO2017089307A1 (en) 2017-06-01
SA518391585B1 (ar) 2020-10-26
EP3380605A1 (en) 2018-10-03
IL259223B (en) 2022-05-01
KR102067352B1 (ko) 2020-01-16
IT201600117287A1 (it) 2018-05-21
RU2018118964A (ru) 2019-12-26
AU2016359838A1 (en) 2018-05-24
JP2019500030A (ja) 2019-01-10
JP7110096B2 (ja) 2022-08-01

Similar Documents

Publication Publication Date Title
FR3044017B1 (fr) Procede de transfection transitoire pour la production retrovirale
MX2017016688A (es) Nuevas enzimas y sistemas crispr.
CL2021002739A1 (es) Proteína crispr de prevotella y francisella 1 (cpf1) aislada de acidaminococcus sp. bv3l6; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
SA523441205B1 (ar) التحرير المتعدد للجينوم
SA518400623B1 (ar) جينات ديستروفين صغير محسنة ومجموعات إظهارها واستخدامها
EP4269577A3 (en) Nucleobase editors and uses thereof
MX382822B (es) Metodos y productos para transfeccion de celulas.
BR112018010635A2 (pt) linhagens celulares estáveis para a produção retroviral
EA202091673A1 (ru) Способ амплификации нуклеиновых кислот
EP4368715A3 (en) Nucleic acid sequence analysis from single cells
MX2022009242A (es) Producto en desarrollo de analisis de secuenciacion de alineacion y variante.
EP4249036A3 (en) Methods and products for nucleic acid production and delivery
EA201890012A1 (ru) Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вич
EP4406585A3 (en) Nucleic acid products and methods of administration thereof
MX2022002872A (es) Nuevas sistemas y enzimas de crispr dirigidos a adn.
WO2016100955A3 (en) Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins
MX2017004285A (es) Indicador biologico.
WO2016061232A3 (en) Multiplexed shrnas and uses thereof
EP3843870C0 (en) MULTIPLE CHARGED IONIC COMPOUNDS DERIVED FROM POLYAMINES AND COMPOSITIONS BASED ON THESE COMPOUNDS AND ASSOCIATED PREPARATION METHODS
GB2564296A (en) Replicative transposon system
EA201070229A1 (ru) Нуклеотидные последовательности msca1, влияющие на мужскую фертильность растений, и способ их применения
BR112013018744A2 (pt) método para produzir um polipetídeo ou uma proteína recombinante
MX2022002315A (es) Anticuerpos anti-cd96 y sus metodos de uso.
MX378585B (es) Sistema de expresion bacterial bicistronico
WO2018067582A3 (en) Hiv-1 env fusion peptide immunogens and their use

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3

PLSC Publication of the preliminary search report

Effective date: 20181026

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20250705